edifoligide

Home
Ligands
edifoligide

GtoPdb Ligand ID: 13633

Synonyms: CGT-003 | CGT003 | E2F Duplex Decoy

Comment: Edifoligide is an oligonucleotide decoy that binds to and inhibits activity of E2F transcription factors that regulate expression of genes controlling smooth muscle cell proliferation. This is proposed as a mechanism to reduce the progressive neointimal hyperplasia that contributes to vein graft failure following coronary artery bypass graft (CABG) surgery [2-4].

References
1. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson Jr TB, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D et al.. (2005) Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA, 294 (19): 2446-54. [PMID:16287955]
2. Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT et al.. (2014) Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg, 149 (8): 798-805. [PMID:25073921]
3. Hoel AW, Conte MS. (2007) Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass. Cardiovasc Drug Rev, 25 (3): 221-34. [PMID:17919257]
4. Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM et al.. (2012) Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J, 164 (3): 379-386.e1. [PMID:22980305]

References

1. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson Jr TB, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D et al.. (2005)
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
JAMA, 294 (19): 2446-54. [PMID:16287955]

2. Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT et al.. (2014)
Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial.
JAMA Surg, 149 (8): 798-805. [PMID:25073921]

3. Hoel AW, Conte MS. (2007)
Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass.
Cardiovasc Drug Rev, 25 (3): 221-34. [PMID:17919257]

4. Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM et al.. (2012)
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.
Am Heart J, 164 (3): 379-386.e1. [PMID:22980305]